primary antibodies against arid1a Search Results


93
Santa Cruz Biotechnology arid1a
a – c Heatmaps of the expression of different repetitive sequences in wild-type (WT) and <t>ARID1A</t> knockout (KO) HCT116 cells. The differential expression is tested based on a model using the negative binomial distribution by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test). The adjusted p values are labeled as * p < 0.05, ** p < 0.01. The schematic of a typical full-length HERVH element is shown in c . d Scatter plot of the expression of all 580 ERVs in WT and KO HCT116 cells. The up (red) and down (green) regulated ERVs are determined by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test) using cut-off values of adjusted p value <0.05 and |Log 2 FC | > 1. e Venn diagram showing that HERVH is repetitively upregulated in three independent sequencing experiments with HCT116 ARID1A WT and KO cells. f Western blots of different ARID1A WT and KO cell lines. Results are representative of three independent experiments. g , h qPCR analyses of HERVH expression in ARID1A WT and KO cell lines using two different primer sets. Data are presented as mean values ± SD from at least three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001, **** p < 0.0001. i Western blots showing ARID1A protein levels in WT, KO, and ARID1A rescued KO HCT116 cells. Results are representative of three independent experiments. Arrow indicates the full-length ARID1A band. j qPCR analysis of ARID1A and HERVH expression in the indicated cells. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05. k qPCR analysis of ARID1B and HERVH expression. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ns: not significant, ** p < 0.01. Source data including exact p -values are provided as a Source data file.
Arid1a, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A+shRNA+Plasmid/pmc09205910-352-27-33
Average 93 stars, based on 1 article reviews
arid1a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
VectorBuilder GmbH gfp-arid1a wt
a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and <t>ARID1A</t> KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.
Gfp Arid1a Wt, supplied by VectorBuilder GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/gfp+arid1a+wt/pmc11711288-265-5-11
Average 90 stars, based on 1 article reviews
gfp-arid1a wt - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

99
Thermo Fisher arid1a
a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and <t>ARID1A</t> KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.
Arid1a, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/TRIS-HCL/us09982304-571-5-40
Average 99 stars, based on 1 article reviews
arid1a - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare arid1a protein
a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and <t>ARID1A</t> KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.
Arid1a Protein, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/pcdna6+v5+arid1a/10__1038_slash_467254a-46-32-14
Average 90 stars, based on 1 article reviews
arid1a protein - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
OriGene rc218151
a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and <t>ARID1A</t> KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.
Rc218151, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A+(NM_006015)+Human+Tagged+ORF+Clone/pm26614907-26-15-13
Average 90 stars, based on 1 article reviews
rc218151 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology antibodies against pgr
a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and <t>ARID1A</t> KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.
Antibodies Against Pgr, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A+Antibody/pm26378916-310-14-18
Average 94 stars, based on 1 article reviews
antibodies against pgr - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Bio-Techne corporation arid1a antibody
a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and <t>ARID1A</t> KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.
Arid1a Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A+Antibody/custom%40nbp1-88932%4030277666
Average 94 stars, based on 1 article reviews
arid1a antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc arid1a rabbit mab cat
Fig. 1 BR0063 demonstrates good in vitro activity, and efficiently inhibits PRC2 in SWI/SNF LOF mutation cell lines. A AlphaScreen assay detection of the inhibitory effect of BR0063 on the interaction of EED with the H3K27me3 peptide. Each experimental condition was performed in duplicate, and error bars are presented as the mean ± SD. B Western blotting (WB) detection of the SWI/SNF subunits <t>ARID1A</t> and SMARCA4 in selected SWI/SNF mutated cell lines. C ELISA detection of H3K27me3 and Histone H3 in cells incubated with serial dilution of BR0063 for 3 days, normalized with DMSO control. Each experiment was performed in duplicate, and error bars are shown as the mean ± SD. D CellTiter-Glo® detection of cell viability of cells incubated with serial dilution of BR0063 for 14 days, normalized with DMSO control. The calculated EC50 values for DMS 114, MFE-296, HuTu-80, and TOV-112D cells are 4.4, 13.7, 79.3, and 132 nM, respectively. Each experiment was performed in triplicate, and the error bars represented the mean ± SD.
Arid1a Rabbit Mab Cat, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A%2FBAF250A+Rabbit+mAb/pm39500892-127-23-28
Average 96 stars, based on 1 article reviews
arid1a rabbit mab cat - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Addgene inc pcdna6 arid1a
Fig. 1 BR0063 demonstrates good in vitro activity, and efficiently inhibits PRC2 in SWI/SNF LOF mutation cell lines. A AlphaScreen assay detection of the inhibitory effect of BR0063 on the interaction of EED with the H3K27me3 peptide. Each experimental condition was performed in duplicate, and error bars are presented as the mean ± SD. B Western blotting (WB) detection of the SWI/SNF subunits <t>ARID1A</t> and SMARCA4 in selected SWI/SNF mutated cell lines. C ELISA detection of H3K27me3 and Histone H3 in cells incubated with serial dilution of BR0063 for 3 days, normalized with DMSO control. Each experiment was performed in duplicate, and error bars are shown as the mean ± SD. D CellTiter-Glo® detection of cell viability of cells incubated with serial dilution of BR0063 for 14 days, normalized with DMSO control. The calculated EC50 values for DMS 114, MFE-296, HuTu-80, and TOV-112D cells are 4.4, 13.7, 79.3, and 132 nM, respectively. Each experiment was performed in triplicate, and the error bars represented the mean ± SD.
Pcdna6 Arid1a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/pcDNA6-ARID1A+(Plasmid+%2339311)/pm40170512-75-15-16
Average 93 stars, based on 1 article reviews
pcdna6 arid1a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
Cell Signaling Technology Inc anti arid1a
Fig. 1 BR0063 demonstrates good in vitro activity, and efficiently inhibits PRC2 in SWI/SNF LOF mutation cell lines. A AlphaScreen assay detection of the inhibitory effect of BR0063 on the interaction of EED with the H3K27me3 peptide. Each experimental condition was performed in duplicate, and error bars are presented as the mean ± SD. B Western blotting (WB) detection of the SWI/SNF subunits <t>ARID1A</t> and SMARCA4 in selected SWI/SNF mutated cell lines. C ELISA detection of H3K27me3 and Histone H3 in cells incubated with serial dilution of BR0063 for 3 days, normalized with DMSO control. Each experiment was performed in duplicate, and error bars are shown as the mean ± SD. D CellTiter-Glo® detection of cell viability of cells incubated with serial dilution of BR0063 for 14 days, normalized with DMSO control. The calculated EC50 values for DMS 114, MFE-296, HuTu-80, and TOV-112D cells are 4.4, 13.7, 79.3, and 132 nM, respectively. Each experiment was performed in triplicate, and the error bars represented the mean ± SD.
Anti Arid1a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A%2FBAF250A+Mouse+mAb/pm38229120-59-8-10
Average 92 stars, based on 1 article reviews
anti arid1a - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology arid1a sirna
Figure 1 <t>ARID1A</t> was downregulated in NPC tissues and cell lines. (A) ARID1A expression in noncancerous nasopharyngeal biopsies and NPC tissues based on IHC. a: High expression of ARID1A in noncancerous nasopharyngeal epithelia; b: Low expression of ARID1A in NPC biopsies; c: High expression of ARID1A in NPC biopsies. The brown staining indicates ARID1A immunoreactivity. (B) ARID1A expression was significantly lower in the NPC biopsies than in the noncancerous nasopharyngeal biopsies. (C–D) Expression levels of ARID1A in the indicated nasopharyngeal epithelial and NPC cell lines were examined by qRT-PCR (C) and Western blotting (D). Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A; IHC, immunohistochemical staining.
Arid1a Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A+siRNA/10__2147_slash_cmar__s207329-55-14-17
Average 93 stars, based on 1 article reviews
arid1a sirna - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
ATCC human ovarian adenocarcinoma
Figure 1 <t>ARID1A</t> was downregulated in NPC tissues and cell lines. (A) ARID1A expression in noncancerous nasopharyngeal biopsies and NPC tissues based on IHC. a: High expression of ARID1A in noncancerous nasopharyngeal epithelia; b: Low expression of ARID1A in NPC biopsies; c: High expression of ARID1A in NPC biopsies. The brown staining indicates ARID1A immunoreactivity. (B) ARID1A expression was significantly lower in the NPC biopsies than in the noncancerous nasopharyngeal biopsies. (C–D) Expression levels of ARID1A in the indicated nasopharyngeal epithelial and NPC cell lines were examined by qRT-PCR (C) and Western blotting (D). Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A; IHC, immunohistochemical staining.
Human Ovarian Adenocarcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+arid1a/SK-OV-3%3B+Ovarian+Adenocarcinoma%3B+Human/pmc04065804-145-57-55
Average 96 stars, based on 1 article reviews
human ovarian adenocarcinoma - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


a – c Heatmaps of the expression of different repetitive sequences in wild-type (WT) and ARID1A knockout (KO) HCT116 cells. The differential expression is tested based on a model using the negative binomial distribution by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test). The adjusted p values are labeled as * p < 0.05, ** p < 0.01. The schematic of a typical full-length HERVH element is shown in c . d Scatter plot of the expression of all 580 ERVs in WT and KO HCT116 cells. The up (red) and down (green) regulated ERVs are determined by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test) using cut-off values of adjusted p value <0.05 and |Log 2 FC | > 1. e Venn diagram showing that HERVH is repetitively upregulated in three independent sequencing experiments with HCT116 ARID1A WT and KO cells. f Western blots of different ARID1A WT and KO cell lines. Results are representative of three independent experiments. g , h qPCR analyses of HERVH expression in ARID1A WT and KO cell lines using two different primer sets. Data are presented as mean values ± SD from at least three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001, **** p < 0.0001. i Western blots showing ARID1A protein levels in WT, KO, and ARID1A rescued KO HCT116 cells. Results are representative of three independent experiments. Arrow indicates the full-length ARID1A band. j qPCR analysis of ARID1A and HERVH expression in the indicated cells. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05. k qPCR analysis of ARID1B and HERVH expression. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ns: not significant, ** p < 0.01. Source data including exact p -values are provided as a Source data file.

Journal: Nature Communications

Article Title: ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription

doi: 10.1038/s41467-022-31197-4

Figure Lengend Snippet: a – c Heatmaps of the expression of different repetitive sequences in wild-type (WT) and ARID1A knockout (KO) HCT116 cells. The differential expression is tested based on a model using the negative binomial distribution by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test). The adjusted p values are labeled as * p < 0.05, ** p < 0.01. The schematic of a typical full-length HERVH element is shown in c . d Scatter plot of the expression of all 580 ERVs in WT and KO HCT116 cells. The up (red) and down (green) regulated ERVs are determined by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test) using cut-off values of adjusted p value <0.05 and |Log 2 FC | > 1. e Venn diagram showing that HERVH is repetitively upregulated in three independent sequencing experiments with HCT116 ARID1A WT and KO cells. f Western blots of different ARID1A WT and KO cell lines. Results are representative of three independent experiments. g , h qPCR analyses of HERVH expression in ARID1A WT and KO cell lines using two different primer sets. Data are presented as mean values ± SD from at least three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001, **** p < 0.0001. i Western blots showing ARID1A protein levels in WT, KO, and ARID1A rescued KO HCT116 cells. Results are representative of three independent experiments. Arrow indicates the full-length ARID1A band. j qPCR analysis of ARID1A and HERVH expression in the indicated cells. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05. k qPCR analysis of ARID1B and HERVH expression. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ns: not significant, ** p < 0.01. Source data including exact p -values are provided as a Source data file.

Article Snippet: 50 μL of supernatant from each sample was reserved as input, and the rest lysate was incubated overnight at 4 °C with the magnetic beads bound with ARID1A (Cell Signaling, 12354 S), ARID1B (Santa Cruz, sc-32762X), SMARCA4 (Abcam, ab110641) or H3K27ac (Abcam, ab4729) antibody respectively.

Techniques: Expressing, Knock-Out, Quantitative Proteomics, Two Tailed Test, Labeling, Sequencing, Western Blot

a – c Heatmaps of the expression levels of different repetitive sequences in WT or ARID1A KO HCT116 cells treated with control or ARID1B (KD) shRNA generated with the GSE101966 dataset. d qPCR results showing the expression levels of ARID1B and HERVH in ARID1A WT or KO cells treated with shRNA targeting GFP or ARID1B. Two different shRNA sequences targeting ARID1B are used to exclude potential off-target effects. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001. e qPCR analysis of ARID1B and HERVH expression levels in ARID1A KO cells treated with the indicated shRNAs and overexpression plasmids. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05, ** p < 0.01, *** p < 0.001. f Heatmap showing the expression levels of the derepressed HERVH loci (27) in ARID1A KO cells determined by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test, using cut-off values of adjusted p value <0.05 and |Log2 FC | > 0.585). The majority of them (25) display reduced expression when ARID1B is knocked down (KO-KD). g Genomic snapshot of RNA-seq signals at a representative HERVH locus ( HERVH_3 ). Two primer sets targeting this locus for ChIP-qPCR analysis are shown. h – j ChIP-qPCR results with two different primer sets showing decreased ARID1A and increased ARID1B at the HERVH_3 locus in ARID1A KO cells, whereas the amount of another BAF component SMARCA4 remains unchanged. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ns: not significant, * p < 0.05, ** p < 0.01, **** p < 0.0001. Source data including exact p values are provided as a Source data file.

Journal: Nature Communications

Article Title: ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription

doi: 10.1038/s41467-022-31197-4

Figure Lengend Snippet: a – c Heatmaps of the expression levels of different repetitive sequences in WT or ARID1A KO HCT116 cells treated with control or ARID1B (KD) shRNA generated with the GSE101966 dataset. d qPCR results showing the expression levels of ARID1B and HERVH in ARID1A WT or KO cells treated with shRNA targeting GFP or ARID1B. Two different shRNA sequences targeting ARID1B are used to exclude potential off-target effects. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001. e qPCR analysis of ARID1B and HERVH expression levels in ARID1A KO cells treated with the indicated shRNAs and overexpression plasmids. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05, ** p < 0.01, *** p < 0.001. f Heatmap showing the expression levels of the derepressed HERVH loci (27) in ARID1A KO cells determined by DESeq2 (version v1.22.2, with two-tailed likelihood ratio test, using cut-off values of adjusted p value <0.05 and |Log2 FC | > 0.585). The majority of them (25) display reduced expression when ARID1B is knocked down (KO-KD). g Genomic snapshot of RNA-seq signals at a representative HERVH locus ( HERVH_3 ). Two primer sets targeting this locus for ChIP-qPCR analysis are shown. h – j ChIP-qPCR results with two different primer sets showing decreased ARID1A and increased ARID1B at the HERVH_3 locus in ARID1A KO cells, whereas the amount of another BAF component SMARCA4 remains unchanged. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ns: not significant, * p < 0.05, ** p < 0.01, **** p < 0.0001. Source data including exact p values are provided as a Source data file.

Article Snippet: 50 μL of supernatant from each sample was reserved as input, and the rest lysate was incubated overnight at 4 °C with the magnetic beads bound with ARID1A (Cell Signaling, 12354 S), ARID1B (Santa Cruz, sc-32762X), SMARCA4 (Abcam, ab110641) or H3K27ac (Abcam, ab4729) antibody respectively.

Techniques: Expressing, Control, shRNA, Generated, Two Tailed Test, Over Expression, RNA Sequencing, ChIP-qPCR

a Schematic showing a full-length HERVH element and the regions targeted by three different shRNAs. b The viability of WT and ARID1A KO HCT116 cells after treatment with shRNA targeting GFP control or HERVH. Three different HERVH shRNAs are used to avoid the possible off-target effects. Data presented are from at least three independent experiments. c Clonogenic assay showing reduced colony formation in the indicated cells treated with different HERVH shRNAs. Results are representative of three independent experiments. d Schematic illustrating the establishment and subsequent treatments of the patient-derived CRC organoids. e , f HERVH knockdowns decrease both the number and the size of CRC organoids. Data are presented as mean values ± SD from at least three independent experiments, two-tailed unpaired t test, * p < 0.05, *** p < 0.001, **** p < 0.0001. g Percentages of Ki67- or TUNEL-positive cells in control and HERVH shRNA treated CRC organoids. Data presented are from three independent experiments. **** p < 0.0001 by chi-squared test. h , i Representative images of control and HERVH shRNA treated organoids stained with E-Cadherin (green), Ki67 (red), TUNEL (yellow), and DAPI (blue). Results are representative of three independent experiments. Bars: 34 μm. Source data including exact n numbers and p values are provided as a Source data file.

Journal: Nature Communications

Article Title: ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription

doi: 10.1038/s41467-022-31197-4

Figure Lengend Snippet: a Schematic showing a full-length HERVH element and the regions targeted by three different shRNAs. b The viability of WT and ARID1A KO HCT116 cells after treatment with shRNA targeting GFP control or HERVH. Three different HERVH shRNAs are used to avoid the possible off-target effects. Data presented are from at least three independent experiments. c Clonogenic assay showing reduced colony formation in the indicated cells treated with different HERVH shRNAs. Results are representative of three independent experiments. d Schematic illustrating the establishment and subsequent treatments of the patient-derived CRC organoids. e , f HERVH knockdowns decrease both the number and the size of CRC organoids. Data are presented as mean values ± SD from at least three independent experiments, two-tailed unpaired t test, * p < 0.05, *** p < 0.001, **** p < 0.0001. g Percentages of Ki67- or TUNEL-positive cells in control and HERVH shRNA treated CRC organoids. Data presented are from three independent experiments. **** p < 0.0001 by chi-squared test. h , i Representative images of control and HERVH shRNA treated organoids stained with E-Cadherin (green), Ki67 (red), TUNEL (yellow), and DAPI (blue). Results are representative of three independent experiments. Bars: 34 μm. Source data including exact n numbers and p values are provided as a Source data file.

Article Snippet: 50 μL of supernatant from each sample was reserved as input, and the rest lysate was incubated overnight at 4 °C with the magnetic beads bound with ARID1A (Cell Signaling, 12354 S), ARID1B (Santa Cruz, sc-32762X), SMARCA4 (Abcam, ab110641) or H3K27ac (Abcam, ab4729) antibody respectively.

Techniques: shRNA, Control, Clonogenic Assay, Derivative Assay, Two Tailed Test, TUNEL Assay, Staining

a PCA analysis showing the impacts of HERVH knockdown on the global transcriptome of WT and ARID1A KO HCT116 cells. b Heatmap highlighting a set of genes whose expressions increase upon ARID1A loss but decrease again when HERVH is knocked down. c KEGG enrichment analysis of the HERVH-dependent genes. Fisher’s exact test (one-tailed) is performed. d , e qPCR validation of representative HERVH-dependent genes. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001, **** p < 0.0001. f Correlation matrix showing the unbiased and pairwise comparisons of global transcriptomes upon knockdown of HERVH and the components in mediator complex. Color bar represents Spearman’s correlation coefficient (one-tailed test). g Heatmap showing strong correlation of changes in transcriptome between knockdowns of HERVH and BRD4 in ARID1A KO HCT116 cells. Spearman’s correlation coefficient Cor = 0.79, p < 0.0001 (one-tailed test). h Venn diagram showing that 1018 genes are coregulated by BRD4 and HERVH. i Partial colocalization between HERVH FISH signals and GFP-BRD4 nuclear foci. Results are representative of three independent experiments. Bar: 5 μm. Source data including exact p values are provided as a Source data file.

Journal: Nature Communications

Article Title: ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription

doi: 10.1038/s41467-022-31197-4

Figure Lengend Snippet: a PCA analysis showing the impacts of HERVH knockdown on the global transcriptome of WT and ARID1A KO HCT116 cells. b Heatmap highlighting a set of genes whose expressions increase upon ARID1A loss but decrease again when HERVH is knocked down. c KEGG enrichment analysis of the HERVH-dependent genes. Fisher’s exact test (one-tailed) is performed. d , e qPCR validation of representative HERVH-dependent genes. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001, **** p < 0.0001. f Correlation matrix showing the unbiased and pairwise comparisons of global transcriptomes upon knockdown of HERVH and the components in mediator complex. Color bar represents Spearman’s correlation coefficient (one-tailed test). g Heatmap showing strong correlation of changes in transcriptome between knockdowns of HERVH and BRD4 in ARID1A KO HCT116 cells. Spearman’s correlation coefficient Cor = 0.79, p < 0.0001 (one-tailed test). h Venn diagram showing that 1018 genes are coregulated by BRD4 and HERVH. i Partial colocalization between HERVH FISH signals and GFP-BRD4 nuclear foci. Results are representative of three independent experiments. Bar: 5 μm. Source data including exact p values are provided as a Source data file.

Article Snippet: 50 μL of supernatant from each sample was reserved as input, and the rest lysate was incubated overnight at 4 °C with the magnetic beads bound with ARID1A (Cell Signaling, 12354 S), ARID1B (Santa Cruz, sc-32762X), SMARCA4 (Abcam, ab110641) or H3K27ac (Abcam, ab4729) antibody respectively.

Techniques: Knockdown, One-tailed Test, Biomarker Discovery, Two Tailed Test

a Representative images and quantifications of GFP-BRD4 nuclear foci in control shNT ( n = 52), shHERVH#2 ( n = 72), or shHERVH#1 ( n = 71) treated cells. The box-plot center represents median, the bottom and top lines represent the 25th and 75th percentiles, the whiskers extending to ±1.5× interquartile range (IQR). Data presented are from three independent experiments, two-tailed unpaired t test, ** p < 0.01, **** p < 0.0001. Bar: 5 μm. b Fluorescence recovery after photobleaching (FRAP) analysis of BRD4 foci after control (NT) or HERVH knockdown. Data are presented as mean values ± SD from at least three independent experiments. Bar: 3.3 μm. c Western blot showing decreased BRD4 protein level upon knockdown of HERVH in HCT116 ARID1A KO cells. Results are representative of three independent experiments. d Representative images and quantifications of GFP-BRD4 puncta in control vehicle ( n = 27) or 1.5% 1,6-HD ( n = 26) treated cells. The box-plot center represents median, the bottom and top lines represent the 25th and 75th percentiles, the whiskers extending to ±1.5× interquartile range (IQR). Data presented are from three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001. Bar: 5 μm. e , f BRD4 ChIP-qPCR results of a group of known BRD4 target genes in the cells treated with the indicated shRNA or chemical. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05, ** p < 0.01, and *** p < 0.001. g A model summarizing how ARID1A loss upregulates HERVH and hence stimulates BRD4 nuclear foci formation and BRD4-mediated transcription. Red asterisks label potential targets of intervention. Source data including exact p values are provided as a Source data file.

Journal: Nature Communications

Article Title: ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription

doi: 10.1038/s41467-022-31197-4

Figure Lengend Snippet: a Representative images and quantifications of GFP-BRD4 nuclear foci in control shNT ( n = 52), shHERVH#2 ( n = 72), or shHERVH#1 ( n = 71) treated cells. The box-plot center represents median, the bottom and top lines represent the 25th and 75th percentiles, the whiskers extending to ±1.5× interquartile range (IQR). Data presented are from three independent experiments, two-tailed unpaired t test, ** p < 0.01, **** p < 0.0001. Bar: 5 μm. b Fluorescence recovery after photobleaching (FRAP) analysis of BRD4 foci after control (NT) or HERVH knockdown. Data are presented as mean values ± SD from at least three independent experiments. Bar: 3.3 μm. c Western blot showing decreased BRD4 protein level upon knockdown of HERVH in HCT116 ARID1A KO cells. Results are representative of three independent experiments. d Representative images and quantifications of GFP-BRD4 puncta in control vehicle ( n = 27) or 1.5% 1,6-HD ( n = 26) treated cells. The box-plot center represents median, the bottom and top lines represent the 25th and 75th percentiles, the whiskers extending to ±1.5× interquartile range (IQR). Data presented are from three independent experiments, two-tailed unpaired t test, ** p < 0.01, *** p < 0.001. Bar: 5 μm. e , f BRD4 ChIP-qPCR results of a group of known BRD4 target genes in the cells treated with the indicated shRNA or chemical. Data are presented as mean values ± SD from three independent experiments, two-tailed unpaired t test, * p < 0.05, ** p < 0.01, and *** p < 0.001. g A model summarizing how ARID1A loss upregulates HERVH and hence stimulates BRD4 nuclear foci formation and BRD4-mediated transcription. Red asterisks label potential targets of intervention. Source data including exact p values are provided as a Source data file.

Article Snippet: 50 μL of supernatant from each sample was reserved as input, and the rest lysate was incubated overnight at 4 °C with the magnetic beads bound with ARID1A (Cell Signaling, 12354 S), ARID1B (Santa Cruz, sc-32762X), SMARCA4 (Abcam, ab110641) or H3K27ac (Abcam, ab4729) antibody respectively.

Techniques: Control, Two Tailed Test, Fluorescence, Knockdown, Western Blot, ChIP-qPCR, shRNA

a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and ARID1A KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency

doi: 10.1038/s41467-024-55637-5

Figure Lengend Snippet: a Schematic of genome-scale CRISPR-Cas9 screen layout. WT and ARID1A KO (clone 2 and 24) U2-OS cells stably expressing Cas9 were infected with the genome-wide Brunello library at a multiplicity of infection (MOI) 0.3 at 500× representation. 48 h post infection, cells were selected with puromycin for a further 6 days. Cells were then treated with ATRi (AZD6738) or DMSO. After 14 days, cells were harvested, the abundance of each sgRNA within the different samples was quantified by next-generation sequencing, and DrugZ software was used to compare read-counts between the different conditions. Created in BioRender. Diab, S. (2025) https://BioRender.com/y46l947 . b , c Rank plots of genes affecting ATRi sensitivity based on DrugZ analysis of results from CRISPR-Cas9 screening in ARID1A WT ( b ), and ARID1A KO ( c ) U2-OS cells; normZ scores show differential effects of gene knockouts with the ATRi compared to DMSO. Selected genes with normZ score of less than (−2) were designated as hypersensitizing hits and are shown in red. Selected genes with normZ score greater than zero were designated resistance hits and are shown in blue. d Biplot for combinational comparison of ATRi modifier genes between WT ( x axis) and ARID1A KO ( y axis) U2-OS cells; z -scores from A and B were used. Differential hits are shown in gold. e Biplot of ARID1A co-essential genes based on DrugZ analysis. Read-counts for DMSO-treated ARID1A KO and WT cells were compared to those of the starting population by using DrugZ separately. f Representative images and quantification of the colony-forming ability of WT and ARID1A KO2 U2-OS cells upon KLF5 siRNA depletion (biological n = 5). Graphs are depicted with means ± SEM. Statistical analyses were performed using one-way ANOVA with multiple comparisons. Source data are provided as a Source Data file.

Article Snippet: GFP only, GFP-KLF5 WT, or GFP-ARID1A WT plasmids were obtained from VectorBuilder.

Techniques: CRISPR, Stable Transfection, Expressing, Infection, Genome Wide, Next-Generation Sequencing, Software, Comparison

Top: KLF5 binds DNA and facilitates BRD4 recruitment to chromatin, thus regulating RNAPII promoter-proximal pausing and transcription elongation in a manner that prevents transcription-associated DNA replication stress. Bottom: Upon KLF5 loss, the recruitment of BRD4 to chromatin is disrupted, causing increased transcription-replication conflicts and downstream events such as DNA replication stress, DNA damage, and increased R-loop accumulation, which when combined with ATR inhibition or with ARID1A deficiency, causes genomic instability and cell death. Created in BioRender. Diab, S. (2025) https://BioRender.com/r68r668 .

Journal: Nature Communications

Article Title: KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency

doi: 10.1038/s41467-024-55637-5

Figure Lengend Snippet: Top: KLF5 binds DNA and facilitates BRD4 recruitment to chromatin, thus regulating RNAPII promoter-proximal pausing and transcription elongation in a manner that prevents transcription-associated DNA replication stress. Bottom: Upon KLF5 loss, the recruitment of BRD4 to chromatin is disrupted, causing increased transcription-replication conflicts and downstream events such as DNA replication stress, DNA damage, and increased R-loop accumulation, which when combined with ATR inhibition or with ARID1A deficiency, causes genomic instability and cell death. Created in BioRender. Diab, S. (2025) https://BioRender.com/r68r668 .

Article Snippet: GFP only, GFP-KLF5 WT, or GFP-ARID1A WT plasmids were obtained from VectorBuilder.

Techniques: Inhibition

Fig. 1 BR0063 demonstrates good in vitro activity, and efficiently inhibits PRC2 in SWI/SNF LOF mutation cell lines. A AlphaScreen assay detection of the inhibitory effect of BR0063 on the interaction of EED with the H3K27me3 peptide. Each experimental condition was performed in duplicate, and error bars are presented as the mean ± SD. B Western blotting (WB) detection of the SWI/SNF subunits ARID1A and SMARCA4 in selected SWI/SNF mutated cell lines. C ELISA detection of H3K27me3 and Histone H3 in cells incubated with serial dilution of BR0063 for 3 days, normalized with DMSO control. Each experiment was performed in duplicate, and error bars are shown as the mean ± SD. D CellTiter-Glo® detection of cell viability of cells incubated with serial dilution of BR0063 for 14 days, normalized with DMSO control. The calculated EC50 values for DMS 114, MFE-296, HuTu-80, and TOV-112D cells are 4.4, 13.7, 79.3, and 132 nM, respectively. Each experiment was performed in triplicate, and the error bars represented the mean ± SD.

Journal: Cell death & disease

Article Title: Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI/SNF loss-of-function tumors.

doi: 10.1038/s41419-024-07109-3

Figure Lengend Snippet: Fig. 1 BR0063 demonstrates good in vitro activity, and efficiently inhibits PRC2 in SWI/SNF LOF mutation cell lines. A AlphaScreen assay detection of the inhibitory effect of BR0063 on the interaction of EED with the H3K27me3 peptide. Each experimental condition was performed in duplicate, and error bars are presented as the mean ± SD. B Western blotting (WB) detection of the SWI/SNF subunits ARID1A and SMARCA4 in selected SWI/SNF mutated cell lines. C ELISA detection of H3K27me3 and Histone H3 in cells incubated with serial dilution of BR0063 for 3 days, normalized with DMSO control. Each experiment was performed in duplicate, and error bars are shown as the mean ± SD. D CellTiter-Glo® detection of cell viability of cells incubated with serial dilution of BR0063 for 14 days, normalized with DMSO control. The calculated EC50 values for DMS 114, MFE-296, HuTu-80, and TOV-112D cells are 4.4, 13.7, 79.3, and 132 nM, respectively. Each experiment was performed in triplicate, and the error bars represented the mean ± SD.

Article Snippet: The membrane was blocked with TBST with 5% BSA, and subsequently incubated with primary antibodies [SMARCA4 rabbit mAb: cat. no. CST#49360, dilution, 1:500; ARID1A rabbit mAb: cat. no. CST#12354, dilution, 1:500; histone H3 rabbit polyclonal antibody: cat. no. CST#9715, dilution, 1:1000; tri-methyl-histone H3 (Lys27) rabbit monoclonal antibody: cat. no. CST#9733, dilution, 1:1000; β-actin rabbit mAb: cat. no. CST#8457, dilution, 1:1000; Rb rabbit mAb: cat. no. CST#9313, dilution 1:500; phospho-Rb (Ser780) rabbit mAb: cat. no. CST#8180, dilution 1:1000; all antibodies provided by CST Biological Reagents Co., Ltd.] diluted in SuperBlockTM Blocking Buffer (cat. no. #37535; Thermo Scientific, Inc.) overnight at 4 °C, and secondary antibody [goat anti-rabbit IgG H&L (HRP): cat. no. #ab205718, dilution 1:4000; Abcam) for 1 h at RT.

Techniques: In Vitro, Activity Assay, Mutagenesis, Amplified Luminescent Proximity Homogenous Assay, Western Blot, Enzyme-linked Immunosorbent Assay, Incubation, Serial Dilution, Control

Figure 1 ARID1A was downregulated in NPC tissues and cell lines. (A) ARID1A expression in noncancerous nasopharyngeal biopsies and NPC tissues based on IHC. a: High expression of ARID1A in noncancerous nasopharyngeal epithelia; b: Low expression of ARID1A in NPC biopsies; c: High expression of ARID1A in NPC biopsies. The brown staining indicates ARID1A immunoreactivity. (B) ARID1A expression was significantly lower in the NPC biopsies than in the noncancerous nasopharyngeal biopsies. (C–D) Expression levels of ARID1A in the indicated nasopharyngeal epithelial and NPC cell lines were examined by qRT-PCR (C) and Western blotting (D). Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A; IHC, immunohistochemical staining.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 1 ARID1A was downregulated in NPC tissues and cell lines. (A) ARID1A expression in noncancerous nasopharyngeal biopsies and NPC tissues based on IHC. a: High expression of ARID1A in noncancerous nasopharyngeal epithelia; b: Low expression of ARID1A in NPC biopsies; c: High expression of ARID1A in NPC biopsies. The brown staining indicates ARID1A immunoreactivity. (B) ARID1A expression was significantly lower in the NPC biopsies than in the noncancerous nasopharyngeal biopsies. (C–D) Expression levels of ARID1A in the indicated nasopharyngeal epithelial and NPC cell lines were examined by qRT-PCR (C) and Western blotting (D). Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A; IHC, immunohistochemical staining.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: Expressing, Staining, Quantitative RT-PCR, Western Blot, Immunohistochemical staining

Figure 2 Low ARID1A expression was associated with advanced TNM stage and poor prognosis in NPC patients. (A) Representative images of ARID1A expression in NPC biopsies with different TNM stages. High expression of ARID1A was observed for the T1, N0, M0, and I stage and DNKC subtype NPC biopsies, while low expression of ARID1A was detected for the T4, N3, M1, and IV stage and UDC subtype tumors. (B) Numbers and percentages of cases with high or low expression of ARID1A according to different clinicopathological features. (C) Low ARID1A expression was associated with a poor prognosis in NPC patients. *P<0.05, **P<0.01, #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A; DNKC, differentiated nonkeratinized squamous carcinoma; UDC, undifferentiated nonkeratinized carcinoma.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 2 Low ARID1A expression was associated with advanced TNM stage and poor prognosis in NPC patients. (A) Representative images of ARID1A expression in NPC biopsies with different TNM stages. High expression of ARID1A was observed for the T1, N0, M0, and I stage and DNKC subtype NPC biopsies, while low expression of ARID1A was detected for the T4, N3, M1, and IV stage and UDC subtype tumors. (B) Numbers and percentages of cases with high or low expression of ARID1A according to different clinicopathological features. (C) Low ARID1A expression was associated with a poor prognosis in NPC patients. *P<0.05, **P<0.01, #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A; DNKC, differentiated nonkeratinized squamous carcinoma; UDC, undifferentiated nonkeratinized carcinoma.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: Expressing

Figure 3 Silencing ARID1A promotes NPC cell proliferation, migration and invasion. (A) According to Western blot assay results, ARID1A was successfully knocked down by siRNA in CNE1 and HNE1 cells, which also resulted in Cyclin D1 upregulation. (B) The effects of ARID1A silencing on cell proliferation were measured by CCK8 assay. (C) Cell cycle distribution was analyzed by flow cytometry at 48 hrs post-culture. (D) Relative cell distribution percentage of ARID1A- silenced (si-ARID1A) and control (si-ctrl) NPC cells in each cell cycle phase. (E and F) Motile and invasive activities of the si-ARID1A and si-ctrl groups of NPC cells based on transwell assays. The average number of cells per field was determined from three repeated independent experiments. *P<0.05, **P<0.01, *** or #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 3 Silencing ARID1A promotes NPC cell proliferation, migration and invasion. (A) According to Western blot assay results, ARID1A was successfully knocked down by siRNA in CNE1 and HNE1 cells, which also resulted in Cyclin D1 upregulation. (B) The effects of ARID1A silencing on cell proliferation were measured by CCK8 assay. (C) Cell cycle distribution was analyzed by flow cytometry at 48 hrs post-culture. (D) Relative cell distribution percentage of ARID1A- silenced (si-ARID1A) and control (si-ctrl) NPC cells in each cell cycle phase. (E and F) Motile and invasive activities of the si-ARID1A and si-ctrl groups of NPC cells based on transwell assays. The average number of cells per field was determined from three repeated independent experiments. *P<0.05, **P<0.01, *** or #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: Migration, Western Blot, CCK-8 Assay, Cytometry, Control

Figure 4 Silencing ARID1A was correlated with Akt pathway activation in NPC cells and clinical NPC biopsies. (A) Depletion of endogenous ARID1A by siRNA increased the phosphorylation of Akt in CNE1 and HNE1 cells. (B and C) Representative images revealed that low ARID1A expression levels were significantly associated with high p-Akt levels in NPC biopsies. #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 4 Silencing ARID1A was correlated with Akt pathway activation in NPC cells and clinical NPC biopsies. (A) Depletion of endogenous ARID1A by siRNA increased the phosphorylation of Akt in CNE1 and HNE1 cells. (B and C) Representative images revealed that low ARID1A expression levels were significantly associated with high p-Akt levels in NPC biopsies. #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: Activation Assay, Phospho-proteomics, Expressing

Figure 5 MK-2206 partially rescued the increased proliferation induced by ARID1A silencing in NPC cells. (A) MK-2206 inhibited proliferation in ARID1A-silenced NPC cells according to a CCK8 assay. (B and C) MK-2206 inhibited G1/S transition in ARID1A-silenced NPC cells according to flow cytometry. *P<0.05, **P<0.01, #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 5 MK-2206 partially rescued the increased proliferation induced by ARID1A silencing in NPC cells. (A) MK-2206 inhibited proliferation in ARID1A-silenced NPC cells according to a CCK8 assay. (B and C) MK-2206 inhibited G1/S transition in ARID1A-silenced NPC cells according to flow cytometry. *P<0.05, **P<0.01, #P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: CCK-8 Assay, Cytometry

Figure 6 MK-2206 partially rescued the enhanced migration and invasion ability induced by ARID1A silencing in NPC cells. (A–C). MK-2206 inhibited the motility (A) and invasion (B) of ARID1A-silenced NPC cells. # P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 6 MK-2206 partially rescued the enhanced migration and invasion ability induced by ARID1A silencing in NPC cells. (A–C). MK-2206 inhibited the motility (A) and invasion (B) of ARID1A-silenced NPC cells. # P<0.001. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: Migration

Figure 7 MK-2206 rescued the changes in Cyclin D1 and EMT-associated markers in ARID1A-silenced NPC cells. Western blot analysis of the expression of ARID1A, p-Akt, Akt, Cyclin D1, E-cadherin and Vimentin. MK-2206 rescued the changes in Cyclin D1, E-cadherin and Vimentin expression in ARID1A-silenced NPC cells. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Journal: Cancer Management and Research

Article Title:

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

doi: 10.2147/cmar.s207329

Figure Lengend Snippet: Figure 7 MK-2206 rescued the changes in Cyclin D1 and EMT-associated markers in ARID1A-silenced NPC cells. Western blot analysis of the expression of ARID1A, p-Akt, Akt, Cyclin D1, E-cadherin and Vimentin. MK-2206 rescued the changes in Cyclin D1, E-cadherin and Vimentin expression in ARID1A-silenced NPC cells. Abbreviations: NPC, nasopharyngeal carcinoma; ARID1A, AT-rich interacting domain-containing protein 1A.

Article Snippet: Transient siRNA transfection ARID1A depletion was performed by transfecting CNE1 and HNE1 cells with ARID1A siRNA (sc-43628, Santa Cruz Biotech, CA, USA).

Techniques: Western Blot, Expressing